These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 36761744)

  • 21. MTHFD2 is a potential oncogene for its strong association with poor prognosis and high level of immune infiltrates in urothelial carcinomas of bladder.
    Zhu L; Liu X; Zhang W; Hu H; Wang Q; Xu K
    BMC Cancer; 2022 May; 22(1):556. PubMed ID: 35581573
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of tumor antigens and immune subtypes of cholangiocarcinoma for mRNA vaccine development.
    Huang X; Tang T; Zhang G; Liang T
    Mol Cancer; 2021 Mar; 20(1):50. PubMed ID: 33685460
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prognostic value of COL10A1 and its correlation with tumor-infiltrating immune cells in urothelial bladder cancer: A comprehensive study based on bioinformatics and clinical analysis validation.
    Wang X; Bai Y; Zhang F; Li D; Chen K; Wu R; Tang Y; Wei X; Han P
    Front Immunol; 2023; 14():955949. PubMed ID: 37006317
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Dissecting Tumor Antigens and Immune Subtypes of Glioma to Develop mRNA Vaccine.
    Zhong H; Liu S; Cao F; Zhao Y; Zhou J; Tang F; Peng Z; Li Y; Xu S; Wang C; Yang G; Li ZQ
    Front Immunol; 2021; 12():709986. PubMed ID: 34512630
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PRR11 is a prognostic biomarker and correlates with immune infiltrates in bladder urothelial carcinoma.
    Ni W; Yi L; Dong X; Cao M; Zheng J; Wei Q; Yuan C
    Sci Rep; 2023 Feb; 13(1):2051. PubMed ID: 36739300
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Identification of Immune-Related Subtypes and Construction of a Novel Prognostic Model for Bladder Urothelial Cancer.
    Zhang J; Huang C; Yang R; Wang X; Fang B; Mi J; Yuan H; Mo Z; Sun Y
    Biomolecules; 2022 Nov; 12(11):. PubMed ID: 36421685
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification of tumor-specific neoantigens and immune clusters of hepatocellular carcinoma for mRNA vaccine development.
    Li YF; Hou QQ; Zhao S; Chen X; Tang M; Li L
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):623-637. PubMed ID: 36239794
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Construction and validation of a gene signature related to bladder urothelial carcinoma based on immune gene analysis.
    Xing P; Jiang Z; Liu Y
    BMC Cancer; 2022 Aug; 22(1):926. PubMed ID: 36030212
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Comprehensive Analyses of Immune Subtypes of Stomach Adenocarcinoma for mRNA Vaccination.
    You W; Ouyang J; Cai Z; Chen Y; Wu X
    Front Immunol; 2022; 13():827506. PubMed ID: 35874675
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Integrated Analysis of Energy Metabolism Signature-Identified Distinct Subtypes of Bladder Urothelial Carcinoma.
    Zhang F; Liang J; Feng D; Liu S; Wu J; Tang Y; Liu Z; Lu Y; Wang X; Wei X
    Front Cell Dev Biol; 2022; 10():814735. PubMed ID: 35281080
    [No Abstract]   [Full Text] [Related]  

  • 31. Identification of tumor antigens and immune subtypes in head and neck squamous cell carcinoma for mRNA vaccine development.
    Chen Y; Jiang N; Chen M; Sui B; Liu X
    Front Cell Dev Biol; 2022; 10():1064754. PubMed ID: 36467412
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The comprehensive and systematic identification of BLCA-specific SF-regulated, survival-related AS events.
    Liu Z; Liu X; Liu F; Zhao H; Zhang Y; Wang Y; Ma Y; Wang F; Zhang W; Petinrin OO; Yao Z; Liang J; He Q; Feng D; Wang L; Wong KC
    Gene; 2022 Aug; 835():146657. PubMed ID: 35710083
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Robust pyroptosis risk score guides the treatment options and predicts the prognosis of bladder carcinoma.
    Deng D; Liu F; Liu Z; Wu Z; He Y; Zhang C; Zu X; Ou Z; Wang Y
    Front Immunol; 2022; 13():965469. PubMed ID: 36090967
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Analysis of melanoma tumor antigens and immune subtypes for the development of mRNA vaccine.
    Ping H; Yu W; Gong X; Tong X; Lin C; Chen Z; Cai C; Guo K; Ke H
    Invest New Drugs; 2022 Dec; 40(6):1173-1184. PubMed ID: 35962880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. PVT1 is a prognostic marker associated with immune invasion of bladder urothelial carcinoma.
    Li P; Qiao G; Lu J; Ji W; Gao C; Qi F
    Math Biosci Eng; 2022 Jan; 19(1):169-190. PubMed ID: 34902986
    [TBL] [Abstract][Full Text] [Related]  

  • 36. An effective N6-methyladenosine-related long non-coding RNA prognostic signature for predicting the prognosis of patients with bladder cancer.
    Ma T; Wang X; Meng L; Liu X; Wang J; Zhang W; Tian Z; Zhang Y
    BMC Cancer; 2021 Nov; 21(1):1256. PubMed ID: 34802433
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Identifying novel tumor-related antigens and immune phenotypes for developing mRNA vaccines in lung adenocarcinoma.
    Zhou B; Zang R; Zhang M; Song P; Liu L; Bie F; Peng Y; Bai G; Gao S
    Int Immunopharmacol; 2022 Aug; 109():108816. PubMed ID: 35504200
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Tumor-antigens and immune landscapes identification for prostate adenocarcinoma mRNA vaccine.
    Zheng X; Xu H; Yi X; Zhang T; Wei Q; Li H; Ai J
    Mol Cancer; 2021 Dec; 20(1):160. PubMed ID: 34872584
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic significance of SNCA and its methylation in bladder cancer.
    Wu Z; Xia C; Zhang C; Yang D; Ma K
    BMC Cancer; 2022 Mar; 22(1):330. PubMed ID: 35346107
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prediction of Prognosis and Recurrence of Bladder Cancer by ECM-Related Genes.
    Zhao H; Chen Z; Fang Y; Su M; Xu Y; Wang Z; Gyamfi MA; Zhao J
    J Immunol Res; 2022; 2022():1793005. PubMed ID: 35450397
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.